Skip to content

Protocols

2016

MSAC Application 1452: Pembrolizumab (MK-3475) in mismatch repair deficient stage IV colorectal carcinoma, December 2016.

MSAC Application 1453: PD-L1 (Programmed Death-1 Ligand) immunohistochemistry testing for access to pembrolizumab for patients with unresectable metastatic mesothelioma, December 2016.

MSAC Application 1457: PD-L1 (Programmed Death 1 Ligand) IHC (immunohistochemistry) testing for access to pembrolizumab as first-line therapy for patients with unresectable or metastatic bladder cancer ineligible for cisplatin-based therapy, December 2016.

2015

MSAC Application 1366: Transient Elastography at 50Hz for diagnosis of Liver Fibrosis in patients with confirmed Hepatitis B or confimed Hepatitis C, May 2015.

MSAC Application 1400: Draft Protocol to guide the assessment of Clinical Neuropsychology Assessment (CNA), August 2015.

MSAC Application 1408: Draft Protocol to guide the assessment of a prognostic RT-qPCR test for ER+ve, HER2-ve primary breast cancer, August 2015.

School of Public Health
The University of Adelaide
Address

Mail Drop 545 or 511
Level 9, Adelaide Health & Medical Sciences Building
SA  5005  AUSTRALIA

Contact

T: +61 8 8313 4617
T: +61 8 8313 3576
ahta@adelaide.edu.au

AHTA Logo